Better off‐site: The binding mechanism of an industrially patented, non‐covalent, nonpeptidic, subunit‐specific immunoproteasome inhibitor was studied. This revealed distinct interactions that account for its isotype‐ and species‐selectivity towards the human immunoproteasome.
                                    更好的异位:研究了一种工业专利的,非共价,非肽,亚基特异性免疫
蛋白酶体
抑制剂的结合机理。这揭示了不同的相互作用,这解释了其对人免疫
蛋白酶体的同种型和物种选择性。